AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39103947 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rTMS and EEG-guided neurofeedback
Number of subjects: 40
Study 39103947 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control Group D)
Number of subjects: 40
Study 39103945 — intervention group
Group type: EXPERIMENTAL
Intervention: Subphenotype 1 (n=156)
Number of subjects: 559
Study 39103945 — intervention group
Group type: COMPARATOR
Intervention: Subphenotype 2 (n=403)
Number of subjects: 559
Study 39103955 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) system implementing VTE prevention clinical practice guidelines (CPGs)
Number of subjects: 0
Study 39103955 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard practice without CDS)
Number of subjects: 0
Study 39103966 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve replacement (TTVR)
Number of subjects: 88
Study 39103966 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 88
Study 39104539 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab, a humanized monoclonal antibody that binds specifically to the IL-36 receptor, antagonizing IL-36 signaling.
Number of subjects: 0
Study 39104539 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dosing of spesolimab for treatment of GPP when not experiencing a flare.
Number of subjects: 0
Study 39104653 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 37
Study 39104653 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 37
Study 39104653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 39104653 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib
Number of subjects: 37
Study 39104721 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 279
Study 39104721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 39105058 — intervention group
Group type: EXPERIMENTAL
Intervention: apitegromab 20 mg/kg by intravenous infusion every 4 weeks
Number of subjects: 35
Study 39105067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab (intravenous every 4-8 weeks, dosage depending on body weight)
Number of subjects: 86
Study 39105117 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged <70 years
Number of subjects: 1251
Study 39105117 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 70 to 79 years
Number of subjects: 1251
Study 39105117 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 80 to 89 years
Number of subjects: 1251
Study 39105117 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged ≥90 years
Number of subjects: 1251
Study 39105131 — intervention group
Group type: EXPERIMENTAL
Intervention: Air travel in patients with pulmonary hypertension
Number of subjects: 60
Study 39105193 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted lobectomy (RAL)
Number of subjects: 320
Study 39105193 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted lobectomy (VAL)
Number of subjects: 320
Study 39105373 — intervention group
Group type: EXPERIMENTAL
Intervention: PMM2-CDG participants
Number of subjects: 14
Study 39105402 — intervention group
Group type: EXPERIMENTAL
Intervention: Powerflow port and ClearVUE power injectable port (new configuration)
Number of subjects: 20
Study 39105794 — intervention group
Group type: EXPERIMENTAL
Intervention: tislelizumab plus low-dose bevacizumab (Bev)
Number of subjects: 32
Study 39105849 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin and nivolumab combination
Number of subjects: 76
Study 39105878 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-78306358
Number of subjects: 39
Study 39105934 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including lifestyle educational program, cognitive and physical training
Number of subjects: 60
Study 39105934 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 60
Study 39105965 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's Symptom Severity (CSS) questionnaire
Number of subjects: 850
Study 39106052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensifentrine
Number of subjects: 0
Study 39106067 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg orally daily for 54 weeks)
Number of subjects: 1545
Study 39106067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1545
Study 39106081 — intervention group
Group type: COMPARATOR
Intervention: GnP (arm A1)
Number of subjects: 181
Study 39106081 — intervention group
Group type: COMPARATOR
Intervention: oleclumab (RP2D) with GnP (arm A2)
Number of subjects: 181
Study 39106081 — intervention group
Group type: COMPARATOR
Intervention: oleclumab (RP2D) with durvalumab plus GnP (arm A3)
Number of subjects: 181
Study 39106081 — intervention group
Group type: EXPERIMENTAL
Intervention: oleclumab 3,000 mg (cohort B)
Number of subjects: 181
Study 39106184 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-item dysexecutive questionnaire
Number of subjects: 0
Study 39106420 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-facilitated cancer symptom control (E2C2)
Number of subjects: 94
Study 39106420 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR systems perceived as acceptable and appropriate
Number of subjects: 94
Study 39106541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabiximols oromucosal spray
Number of subjects: 68
Study 39106541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 39106857 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-ICOS score (risk stratification)
Number of subjects: 1066
Study 39107131 — intervention group
Group type: EXPERIMENTAL
Intervention: nivolumab+ipilimumab
Number of subjects: 201
Study 39107131 — intervention group
Group type: COMPARATOR
Intervention: nivolumab monotherapy
Number of subjects: 201
Study 39107157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (2L therapy)
Number of subjects: 281
Study 39107157 — intervention group
Group type: COMPARATOR
Intervention: Other therapies (2L therapy)
Number of subjects: 281
Study 39107270 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac® (3-μg injections, two doses, 28 days apart)
Number of subjects: 11349
Study 39107270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11349
Study 39107270 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac®
Number of subjects: 11349
Study 39107668 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pain intensity on admission (numerical rating scale 0-10)
Number of subjects: 1240
Study 39107668 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger (numerical rating scale 0-10)
Number of subjects: 1240
Study 39107668 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative self-perceived health
Number of subjects: 1240
Study 39107668 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 1240
Study 39107668 — intervention group
Group type: EXPERIMENTAL
Intervention: Age under 65 years
Number of subjects: 1240
Study 39107671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-specific psychosocial methods from the project 'My Logbook'
Number of subjects: 0
Study 39107706 — intervention group
Group type: EXPERIMENTAL
Intervention: TabCAT-BHA intervention (tablet-based brain health assessment) with practice supports including education, digital tools, and registered nurse support.
Number of subjects: 180000
Study 39107706 — intervention group
Group type: COMPARATOR
Intervention: Usual care clinics (control group).
Number of subjects: 180000
Study 39107737 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxolid implants
Number of subjects: 18
Study 39107737 — intervention group
Group type: COMPARATOR
Intervention: Titanium implants
Number of subjects: 18
Study 39107751 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundling seated exercises and psychological rehabilitation interventions using the teach-back approach
Number of subjects: 60
Study 39107751 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 60
Study 39107793 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) in the morning, afternoon, or evening for 12 weeks, with three 2-week blocks of supervised post-prandial exercise and 2-week washout periods.
Number of subjects: 2
Study 39107820 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and Treatment of Anxiety and Depression (STAND)
Number of subjects: 167
Study 39107820 — intervention group
Group type: EXPERIMENTAL
Intervention: Original online therapy intervention
Number of subjects: 167
Study 39107820 — intervention group
Group type: COMPARATOR
Intervention: Perinatal care delivered by a reproductive psychiatrist
Number of subjects: 167
Study 39107847 — intervention group
Group type: EXPERIMENTAL
Intervention: axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel)
Number of subjects: 925
Study 39107847 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS-PSS score > 2
Number of subjects: 925
Study 39107847 — intervention group
Group type: EXPERIMENTAL
Intervention: ICANS-PSS score > 2
Number of subjects: 925
Study 39107860 — intervention group
Group type: EXPERIMENTAL
Intervention: Group eConsent
Number of subjects: 434
Study 39107968 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided transbronchial biopsy (TBB)
Number of subjects: 89
Study 39107968 — intervention group
Group type: COMPARATOR
Intervention: R-EBUS-guided transbronchial biopsy (TBB)
Number of subjects: 89
Study 39108325 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) at 600 mg twice daily
Number of subjects: 0
Study 39108325 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 0
Study 39108506 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing along to an instructional video for 30 minutes
Number of subjects: 65
Study 39108506 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached singing from an in-person music therapist for 30 minutes
Number of subjects: 65
Study 39108506 — intervention group
Group type: COMPARATOR
Intervention: Control (30-minute rest)
Number of subjects: 65
Study 39108529 — intervention group
Group type: EXPERIMENTAL
Intervention: Installation of concrete floors in homes with soil floors
Number of subjects: 800
Study 39108529 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 800
Study 39108617 — intervention group
Group type: EXPERIMENTAL
Intervention: sacituzumab govitecan (10 mg/kg)
Number of subjects: 1
Study 39108660 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Number of subjects: 898
Study 39109192 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital contact tracing approach using the 'Mamal PRO' platform.
Number of subjects: 313
Study 39109192 — intervention group
Group type: COMPARATOR
Intervention: Standard contact tracing approach.
Number of subjects: 313
Study 39109221 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg ivermectin
Number of subjects: 100
Study 39109241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Relief Patch (PRP) delivering blue light for 30 minutes during five treatment sessions
Number of subjects: 171
Study 39109241 — intervention group
Group type: COMPARATOR
Intervention: Control device delivering green light for 5 seconds but worn for 30 minutes
Number of subjects: 171
Study 39109257 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority stress psychoeducation tool
Number of subjects: 0
Study 39109266 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed microbiota transplantation (WMT), conducted from January 2020 to March 2021.
Number of subjects: 47
Study 39109266 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed microbiota transplantation (WMT)
Number of subjects: 47
Study 39109409 — intervention group
Group type: EXPERIMENTAL
Intervention: EKIT tool (digital decision aid) used in doctor-patient discussion
Number of subjects: 1055
Study 39109409 — intervention group
Group type: COMPARATOR
Intervention: Standard discussion without EKIT tool
Number of subjects: 1055
Study 39109415 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT educational course
Number of subjects: 70
Study 39109429 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalectomy for secondary malignancy
Number of subjects: 2822
Study 39109429 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalectomy for secondary malignancy with radiotherapy within the year before surgery
Number of subjects: 2822
Study 39109429 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adrenalectomy
Number of subjects: 2822
Study 39109797 — intervention group
Group type: EXPERIMENTAL
Intervention: Friedreich's Ataxia (FRDA)
Number of subjects: 11
Study 39109797 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 39110045 — intervention group
Group type: EXPERIMENTAL
Intervention: Crano-cure (500 mg capsules, two times a day for 28 days)
Number of subjects: 205
Study 39110045 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg tablets, two times a day for 28 days)
Number of subjects: 205
Study 39110139 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 2356
Study 39110139 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 2356
Study 39110139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2356
Study 39110139 — intervention group
Group type: COMPARATOR
Intervention: Dupilumab
Number of subjects: 2356
Study 39110191 — intervention group
Group type: EXPERIMENTAL
Intervention: German version of the Parent-Adolescent Communication Scale (PACS)
Number of subjects: 1044
Study 39110191 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent version of PACS in adolescent psychiatry sample
Number of subjects: 1044
Study 39110209 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 points self-monitoring blood glucose
Number of subjects: 200
Study 39110209 — intervention group
Group type: COMPARATOR
Intervention: 7 points self-monitoring blood glucose
Number of subjects: 200
Study 39110318 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine corneal cross-linking (CXL)
Number of subjects: 77
Study 39110318 — intervention group
Group type: COMPARATOR
Intervention: Stable untreated keratoconus
Number of subjects: 77
Study 39110318 — intervention group
Group type: COMPARATOR
Intervention: Age/gender-matched controls
Number of subjects: 77
Study 39110387 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving intervention with workplace involvement (PSI-WPI)
Number of subjects: 197
Study 39110387 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 197
Study 39110421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilta-cel (ciltacabtagene autoleucel)
Number of subjects: 419
Study 39110421 — intervention group
Group type: COMPARATOR
Intervention: Standard therapies
Number of subjects: 419
Study 39110427 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose DOAC (apixaban, 2.5 mg every 12 hours)
Number of subjects: 90
Study 39110427 — intervention group
Group type: COMPARATOR
Intervention: DAPT (aspirin 100 mg per day plus clopidogrel 75 mg per day)
Number of subjects: 90
Study 39110436 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, interactive text message program for vaping cessation that delivers cognitive and behavioral coping skills training and social support (n=759)
Number of subjects: 1503
Study 39110436 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control (n=744)
Number of subjects: 1503
Study 39110454 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (1.00 FiO2)
Number of subjects: 100
Study 39110454 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (minimum FiO2 to maintain oxygen saturation 95%-97%)
Number of subjects: 100
Study 39110461 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual feedback report provided in the VCA application after 2 weeks
Number of subjects: 146
Study 39110461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback until after time 2)
Number of subjects: 146
Study 39110461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (without prior disclosure experience)
Number of subjects: 146
Study 39110461 — intervention group
Group type: COMPARATOR
Intervention: Control group (without prior disclosure experience)
Number of subjects: 146
Study 39110461 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse performance at time 1
Number of subjects: 146
Study 39110471 — intervention group
Group type: EXPERIMENTAL
Intervention: PARADISE-MI trial
Number of subjects: 5661
Study 39110471 — intervention group
Group type: COMPARATOR
Intervention: VALIANT (PARADISE-MI-like) cohort
Number of subjects: 5661
Study 39110497 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based training with machine guidance (MG)
Number of subjects: 62
Study 39110497 — intervention group
Group type: COMPARATOR
Intervention: VR-based training with educator guidance (EG)
Number of subjects: 62
Study 39110497 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between training duration and VR exam scores for MG group
Number of subjects: 62
Study 39110497 — intervention group
Group type: COMPARATOR
Intervention: Correlation between training duration and VR exam scores for EG group
Number of subjects: 62
Study 39110531 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg once daily (QD)
Number of subjects: 0
Study 39110531 — intervention group
Group type: COMPARATOR
Intervention: Exemestane 25 mg 3 times/week (TIW)
Number of subjects: 0
Study 39110531 — intervention group
Group type: COMPARATOR
Intervention: Exemestane 25 mg per week (QW)
Number of subjects: 0
Study 39110721 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixation of B2 PFFs around cemented polished taper-slip stems with an intact bone-cement interface
Number of subjects: 0
Study 39110721 — intervention group
Group type: COMPARATOR
Intervention: Revision surgery for B2 PFFs
Number of subjects: 0
Study 39110846 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (5-20 mg/day)
Number of subjects: 395
Study 39110971 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBTi with chatbot-based coaching and therapist support
Number of subjects: 129
Study 39110971 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBTi with chatbot-based coaching and research assistant support
Number of subjects: 129
Study 39110971 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBTi with chatbot-based coaching only
Number of subjects: 129
Study 39110971 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBTi without any coaching
Number of subjects: 129
Study 39110971 — intervention group
Group type: COMPARATOR
Intervention: digital sleep hygiene and self-monitoring control
Number of subjects: 129
Study 39110971 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBTi with human support
Number of subjects: 129
Study 39111209 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib + Abiraterone Acetate + Prednisone (AAP)
Number of subjects: 225
Study 39111209 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Abiraterone Acetate + Prednisone (AAP)
Number of subjects: 225
Study 39111231 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 301
Study 39111231 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 301
Study 39111386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright IDEAS-Young Adults (Bright IDEAS-YA)
Number of subjects: 0
Study 39111386 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0
Study 39111387 — intervention group
Group type: EXPERIMENTAL
Intervention: Eat Well (intervention arm) - debit card with $80 added monthly for 12 months for fresh, frozen, or canned fruits and vegetables.
Number of subjects: 2400
Study 39111387 — intervention group
Group type: COMPARATOR
Intervention: Control arm - no debit card provided.
Number of subjects: 2400
Study 39111388 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil + CRT
Number of subjects: 160
Study 39111388 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil alone
Number of subjects: 160
Study 39111388 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT alone
Number of subjects: 160
Study 39111388 — intervention group
Group type: COMPARATOR
Intervention: placebos
Number of subjects: 160
Study 39111544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) therapy
Number of subjects: 105
Study 39111544 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 105
Study 39111550 — intervention group
Group type: EXPERIMENTAL
Intervention: Acesulfame-potassium (ace-K)
Number of subjects: 40
Study 39111550 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose
Number of subjects: 40
Study 39111551 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-SFA/higher-UFA diet
Number of subjects: 109
Study 39111800 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression alone
Number of subjects: 267
Study 39111800 — intervention group
Group type: COMPARATOR
Intervention: Decompression with instrumented fusion
Number of subjects: 267
Study 39111800 — intervention group
Group type: EXPERIMENTAL
Intervention: Total from baseline to five years (Decompression alone)
Number of subjects: 267
Study 39111800 — intervention group
Group type: COMPARATOR
Intervention: Total from baseline to five years (Fusion)
Number of subjects: 267
Study 39111953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan 200 mg twice daily
Number of subjects: 900
Study 39111953 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg twice daily
Number of subjects: 900
Study 39112102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) 10 g TID during the OLP
Number of subjects: 270
Study 39112102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 39112464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan (SG) at 10 mg/kg, administered as a single intravenous dose one day before resection and continued on days 1 and 8 of 21-day cycles following recovery.
Number of subjects: 25
Study 39112489 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB (Bexsero, GSK) vaccine, two doses
Number of subjects: 50
Study 39112489 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB (Bexsero, GSK) vaccine
Number of subjects: 50